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Summary 
 
α-Synuclein is implicated in Parkinson’s Disease, a 
neurodegenerative disease that destroys midbrain 
neurons. The misfolding and subsequent 
aggregation of this protein is the likely cause of cell 
death. A major hypothesis in the field is that 
increasing α-synuclein’s rate of degradation may 
prevent its aggregation and toxicity. The prevalent 
model for α-synuclein degradation is via the 
proteasome, and malfunctions in this pathway have 
been shown to increase α-synuclein accumulation 
and toxicity. However, increasing evidence 
suggests that the Multivesicular Body (MVB) 
sorting pathway is involved in protein degradation 
via the lysosome. To test the role of the MVB 
sorting pathway for the degradation of wild-type 
and mutant α-synucleins, we asked if α-synuclein 
would accumulate and increase toxicity in yeast 
that lacked one of the MVB proteins. Previously, 
Price and Shrestha showed that the absence of 
vps28, an MVB protein caused toxicity in yeast 
expressing α-synuclein (Eukaryon). We tested 
another protein, vps34, a PI 3-kinase acting 
upstream in the proteins involved in the MVB 
pathway. The absence of vps34 was toxic to yeast 
and this toxicity was severely exacerbated in the 
presence of any foreign protein, including α-
synuclein. Future research will examine several 
other essential lysosomal pathway factors in 
mediating α-synuclein toxicity.  
 
Introduction 
 
Parkinson’s disease (PD) is the second most common 
neurodegenerative disease affecting about 1 million 
people in North America (Greenamyre and Hastings, 
2004). In PD, dopaminergic neurons in the substantia 
nigra pars compacta (SNpc), in the mid brain die. 
These basal ganglia neurons secrete dopamine which 
is necessary for smooth and coordinated muscle 
movement (Giasson and Lee, 2003). Loss of dopamine 
results in most of the clinical symptoms of PD which 
include resting tremors, slowness of movement, rigidity, 
postural instability, and depression (Wolters and Braak, 
2006). Round eosinophilic inclusions comprised of a 
halo of radiating fibrils, known as Lewy bodies, found 
within SNpc neurons and dystrophic neurites (Lewy 
neurites) are the pathological hallmarks of PD (Giasson 
and Lee, 2003; Dawson and Dawson, 2003). Misfolded 
and aggregated α-synuclein is the primary filamentous 
component of Lewy bodies (Spillantini, 1997; Spillantini 
et al., 1998). 
 α-Synuclein is a 140 amino acid protein 
found in pre-synaptic nerve terminals in neurons 
(Spillantini, 1998; Mclean et al., 2000; Choi et al., 
2004). Although the precise function of α-synuclein is 
unclear, it is known to play a role in synaptic plasticity  
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and remodeling (Kahle et al., 2000). Recently, α-
synuclein was shown to protect nerve terminals against  
injury in conjunction with other synaptic proteins 
(Chandra et al., 2005). Over the past 10 years, three 
missense point mutations in α-synuclein have been 
discovered in families with PD: A30P, A53T, and E46K 
(Polymeropoulos et al., 1997; Kruger et al., 1998; 
Zarranz et al., 2004). These familial mutations on 
chromosome 4 are associated with early-onset PD and 
may cause the misfolding and subsequent aggregation 
of α-synuclein in Lewy bodies (Zabrocki et al., 2005). 
The duplication or triplication of the α-synuclein gene is 
also known to cause PD (Ibanez et al., 2004). In 2001, 
McNaught et al., found that protein degradation is 
impaired by 33-42% in PD patients, providing evidence 
that PD is caused by impaired degradation of α-
synuclein leading to the formation of protein-rich Lewy 
bodies containing misfolded α-synuclein. 
 A possible way of treating PD is by degrading 
misfolded and aggregated α-synuclein. There is genetic 
and chemical evidence to show that α-synuclein is 
degraded by the ubiquitin-proteasome system (UPS; 
Thrower et al., 2000; Holtz and O’Malley, 2003; 
McNaught 2002; Webb et al., 2003). Familial mutations 
in parkin, an E3 ubiquitin ligase, and mutations in 
ubiquitin carboxyL-terminal hydrolase L1 (UCH-L1) 
inhibit the UPS in PD patients (Kitada et al., 1998; 
Leroy et al., 1998). Furthermore, McNaught et al. 
(2002), provided strong evidence that defects in the 
UPS underlie PD pathology and toxicity. 
 Studies have shown that the UPS is not the 
only organelle involved in α-synuclein degradation 
(Webb et al., 2003). In fact, monomeric and aggregated 
α-synuclein has been shown to inhibit the UPS, rather 
than defects in the UPS causing α-synuclein 
aggregation (Snyder et al., 2003). Further, 
pharmacological inhibition of the UPS did lead to an 
increase in cellular levels of α-synuclein (Rideout and 
Stefanis, 2002; Biasini et al., 2004). This suggests that 
another pathway of protein degradation—the 
endosome/lysosome pathway—may be involved. 
 The yeast vacuole acts as the lysosome, 
which degrades extracellular molecules, membrane and 
endo-membrane proteins, and organelles. It also 
degrades nuclear and cytoplasmic proteins, making it a 
possible target for α-synuclein degradation. Webb et 
al., provided evidence that in addition to the 
proteasome, the lysosome also degrades α-synuclein. 
Moreover, inhibition of the lysosome leads to an 
increase in the intracellular levels of α-synuclein (Webb 
et al., 2003; Lee et al., 2004; Cuervo et al., 2004).  
 Proteins are sent to the lysosome via 
endocytic pathways. The multivesicular body (MVB) 
sorting pathway to degradation by the 
lysosome/vacuole sorts proteins that are to be 
degraded by the lysosome by targeting them into the 
lumen of endosomes (Katzmann et al., 2001). Proteins 
that are to be recycled or sent elsewhere are kept at the 
limiting membrane of the endosome (Katzmann et al., 
2002). The fusion of the endosome with the lysosome 
delivers the contents of the MVBs to the lysosome for 
hydrolysis, while proteins on the limiting membrane of 
the MVBs remain on the limiting membrane of the 
lysosome (Katzmann et al., 2001).  
 The MVB sorting pathway is composed of 
more than 15 vacuolar protein sorting (vps) proteins 
which work alone or in complex. Monoubiquitination 
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serves as a recognition signal for proteins to be 
degraded through the MVB sorting pathway (Katzmann 
et al., 2001). The ESCRT-I complex, a 350kDa protein 
complex composed of vps23, vps28, and vps37 
functions downstream of vps27, while vps15 and vps34 
which form a complex are upstream of vps27 
(Katzmann et al., 2003). Vps34 is a PI 3-kinase. Vps27 
is then recruited to the enriched phospholipid layer of 
the endosome membrane, where it can bind 
ubiquitinated MVB cargo and recruit and activate 
ESCRT-I (Katzmann et al., 2003). ESCRT-II and 
ESCRT-III are composed of other vps proteins and act 
downstream of ESCRT-I. Since α-synuclein is known to 
bind membranes (Choi et al., 2004), it may be 
degraded through the MVB sorting pathway to the 
lysosome/vacuole. 
 Previously, our lab showed that knocking out 
vps28, a component of ESCRT-I lead to modest toxicity 
(Price and Shrestha, 2005). We hypothesize that 
knocking out vps34 and expressing wildtype and 
mutant forms of α-synuclein, will cause toxicity, since 
vps34 is required for the proper functioning of the MVB 
sorting pathway to protein degradation by the 
lysosome. 
 An S. cerevisiae model developed in our lab 
(Sharma et al., 2006) was used to assess the lack of 
vps34 with expression of α-synuclein, as yeast have 
already been shown to be useful model systems for the 
study of study neurodegenerative diseases, including 
Huntington’s disease and PD (Outeiro et al., 2003). The 
toxicity of wildtype and mutant (A30P, E46K and A53T) 
α-synucleins was assessed in vps34 mutants using 
growth curve analysis through optical density data and 
dilution serial spotting. Western blotting was done to 
examine the levels of wildtype and mutant α-synucleins 
in vps34 strains. These data shed light on the role of 
vps34 in the degradation of wildtype and mutant α-
synucleins. 
  
Results 
 
Wildtype α-synuclein is toxic to vps34 yeast 
To assess the effects of knocking out vps34 and 
expressing α-synuclein in the cells, an optical density 
analysis at 600 nm was done. Untagged α-synuclein 
was expressed in vps34 yeast by growing cells in 
galactose media. As seen in figure 1, cells lacking 
vps34 showed moderate toxicity. At 24 hours post 
induction, yeast lacking vps34 had barely grown, while 
those with vps34 had an absorbance value of 1.5. 
Strains not expressing any α-synuclein are shown at 
the top graph and serve as controls. These strains were 
grown in SC-Ura glucose (Refer to methods). 
 
Wildtype α-synuclein tagged to GFP is also toxic to 
vps34 yeast 
In order to assess the localization of α-synuclein in 
vps34 yeast, a GFP tag was ligated to the C- terminal 
of the α-synuclein gene (Refer to methods). As seen in 
figure 2, α-synuclein-GFP is highly toxic to vps34 yeast. 
This strain did not grow at all, until about 48 hours, 
however, the parent strain, expressing vps34 and α-
synuclein-GFP had already reached saturation point by 
24 hours. A sharp increase in growth was observed 
after 48 hours in vps34 yeast expressing α-synuclein-
GFP. 
 
GFP alone is extremely toxic to vps34 yeast 
Since the toxicity associated with α-synuclein-GFP was 
greater than that associated with α-synuclein, an optical 
Figure 1. Optical density analysis of α-synuclein in vps34 
yeast. The top graph serves as a control, as cells were grown in 
non inducing media (top). In the bottom graph, cells were grown 
in galactose (inducing media). Yeast lacking vps34 hardly grew 
at the 24 hour time point, compared to the wild type control. 
Figure 2. Growth curve showing growth of wildtype α-
synuclein-GFP in vps34 yeast. When expressing α-synuclein-
GFP, cells lacking vps34 do not grow until about 48 hours, while 
cells with vps34 reach saturation point by 24 hours. 
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density analysis was done in a vps34 strain expressing 
GFP alone. Surprisingly, GFP was extremely toxic to 
vps34 yeast. There was virtually no growth even after 
72 hours. However, the parent strain expressing vps34 
reached saturation density before 24 hours (figure 3). 
 
Another Foreign Protein, LacZ, is also toxic to vps34 
yeast 
Green fluorescent protein (GFP) is a reporter gene 
which is used extensively by scientists to study protein 
localization in model systems. The toxicity associated 
with GFP in vps34 yeast led to the analysis of another 
reporter gene; LacZ. As seen in figure 4, the vps34 
strain expressing LacZ, is highly toxic. There is barely 
any growth in this strain up to 36 hours post induction; 
however, the parent strain reaches saturation in only 36 
hours. In vps34 yeast, toxicity due to expression of 
LacZ is less than the toxicity associated with GFP.  
 
Spotting analysis of vps34 yeast shows high toxicity 
To further analyze the toxicity associated with the 
vps34 strain, a dilution series spotting assay was 
performed. The three familial α-synuclein mutants, 
A30P- α-synuclein, E46K- α-synuclein and A53T- α-
synuclein were transformed in wild type parent strain 
and vps34 yeast. The empty pYES2 plasmid and GFP 
were used as controls. Cells were plated on inducing 
and non-inducing media (figure 5). Vps34 transformants 
can be seen to have grown less than parent strain 
transformants on non-inducing media. In inducing 
media, parent strain transformants grow well. However, 
vps34 transformants do not grow at all, with the 
exception of some growth in the empty pYES2 
transformant. Growth curve data showing toxicity in any 
vps34 transformant expressing foreign proteins 
supported the dilution series spotting data.  
 
Vps34 affects α-synuclein expression 
Western analysis was done on parent strain and the 
vps34 transformants to confirm α-synuclein expression. 
Cell lysates were prepared after 24 hours of protein 
induction. Lysates were run on two gels, one for the 
blotting membrane (figure 6A) and one for the 
Coomassie control (figure 6B). As expected, no protein 
expression was seen in cells transformed with the 
pYES2 vector (lane 1). Lane 2 showed the expected 
size of the green fluorescent protein at about 36 kDa. 
For wildtype and mutant forms of α-synuclein (lanes 3-
6), bands were seen at 60 kDa, which is about 8 kDa 
greater than the standard size of monomeric α-
synuclein. In our S. cerevisiae model, α-synuclein was 
previously shown to consistently migrate 6-8 kDa higher 
than expected (Sharma et al., 2006). Band intensities of 
wildtype and mutant α-synucleins in the parent strain 
(4741) are comparable.  In 4741 transformants, GFP, 
wildtype and mutant α-synucleins showed multiple 
bands, as seen in lanes 2 through 6. This indicates that 
proteins are degraded either during cell lysis or in vivo 
(Sharma et al., 2006). 
In the empty pYES2 vps34 transformant, no 
protein was seen, as expected (lane 7). Importantly, the 
lack of vps34 completely suppressed α-synuclein 
expression (lanes 8-12). 
 
Galactose media is toxic to vps34 yeast 
A growth curve analysis was done with the parent strain 
and vps34 strain grown in SC-Ura glucose and SC-Ura 
galactose (figure 7).  Both strains reach saturation  
Density by the 24 hour time point when grown in non- 
 
 
 
Figure 3. Vps34 yeast expressing GFP are extremely 
toxic. No growth is observed even after 72 hours. Yeast 
expressing vps34 reach saturation by 24 hours post induction. 
 
Figure 4. Growth curve analysis of LacZ in vps34 yeast. In 
inducing media (bottom graph), vps34 yeast expressing LacZ 
do not grow till about 36 hours post induction. At 36 hours, 
cells expressing vps34 and lacZ reach saturation. 
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Figure 6.  α-Synuclein expression in vps34 
(A) Western Blotting. α-synuclein was probed with a Anti–V5 AP 1° antibody. As expected, the empty pYES2 transformant showed no 
protein. A band was seen at 36 kDa corresponding to expected size of GFP. Bands were seen for wildtype and mutant α-synucleins at about 
60 kDa. Multiple bands are seen in lanes 2-6.  No protein was seen for any of the vps34 transformants. 
(B) Coomassie Staining. For parent strain 4741, band intensities are comparable, corresponding to equal amounts of protein being loaded. 
However, for vps34 transformants, bands 7, 8 and 10 are darker, indicating that more protein was loaded in these lanes. 
Figure 5. Dilution series spotting.  
4741 and vps34 transformants were grown on non-inducing (glucose) and inducing (galactose) media. Growth of vps34 yeast was much 
less than parent strain on non-inducing media. When expressing GFP and α-synuclein, vps34 yeast did not grow at all. Slight growth was 
seen in the pYES2 control. 
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inducing media. However, the vps34 strain grown in 
inducing media hardly grew by the 24 hour point, while  
the parent strain reached a density of 1.5. This shows 
that galactose media causes toxicity in vps34 yeast. 
 
Discussion 
 
There is evidence to suggest that impaired degradation 
of α-synuclein leads to the formation of α-synuclein rich 
Lewy bodies (McNaught et al., 2002). Therefore, 
increasing the rate of protein degradation could serve 
as a potential therapy. Genetic and chemical evidence 
points to the role of the ubiquitin proteasome system in 
degrading α-synuclein. However, studies have shown 
that the lysosome also degrades α-synuclein (Webb et 
al., 2003; Lee et al., 2004; Cuervo et al., 2004). 
Absence of vps28, a component of the MVB sorting 
pathway to degradation via the lysosome has been 
shown to increase α-synuclein toxicity (Willingham et 
al., 2003; Price and Shrestha, 2005). In this paper, we 
examined the role of vps34 a PI 3-kinase, in the MVB 
pathway, in mediating α-synuclein toxicity.  
 
Foreign proteins including α-synuclein are toxic to 
vps34 yeast 
Vps34 is a PI 3-kinase which phosphorylates PI on 
endosomes to PI(3)P. Endosomal membranes 
containing PI(3)P, then target vps27 which binds to 
ubiquitinated cargo on endosomes and recruits and 
activates the ESCRT-I complex (Katzmann et al., 
2003). The kinase activity of vps34 is probably not 
restricted to endosomal membranes and is essential for 
survival when foreign proteins, like α-synuclein, GFP 
and LacZ are expressed.  
 The toxicity associated with untagged 
wildtype α-synuclein in vps34 yeast was exacerbated 
when GFP was tagged to the C- terminal of the α-
synuclein gene. This increase in toxicity was shown to 
be caused by the addition of GFP, as α-synuclein alone 
was less toxic to vps34 yeast. This may have occured 
due to some adverse effect of GFP on metabolism in 
vps34 yeast. It can also be possible that α-synuclein 
has a protective function, as α-synuclein-GFP was less 
toxic than GFP alone. Research will have to be 
conducted to study the interactions of GFP in vps34 
yeast. 
Studies using vps34 yeast have previously 
been done (Katzmann et al., 2003); however, parent 
strain 4741 was not used. The extreme toxicity 
observed when expressing wildtype or mutant α-
synuclein, GFP or LacZ is most likely a strain specific 
sensitivity of the 4741 parent strain. Different strains of 
yeast are known to be sensitive to different proteins. 
Unpublished results from our lab show that the E46K- 
α-synuclein mutant is moderately toxic in the 4741 
parent strain, but not in other isogenic strains like 5-1. 
 
α-Synuclein expression in vps34 yeast 
The absence of α-synuclein in the western blot 
analysis, suggests that the cells decreased α-synuclein 
expression in order to survive. Unpublished data from 
our lab, show that in yeast knocked out for α-
ketoglutarate dehydrogenase, a mitochondrial enzyme, 
α-synuclein expression is also greatly reduced. Thus, 
reduction in α-synuclein expression may be used by the 
cell to survive. 
 
Toxicity associated with galactose media 
SC-Ura galactose caused toxicity in untransformed 
vps34 yeast. Yeast prefer glucose, and are known to 
grow slower in galactose media. However, SC-Ura 
galactose caused more than usual toxicity in the 
untransformed vps34 strain. It is possible that vps34 
plays a role in galactose metabolism. This toxicity may 
also be strain specific. The effect of galactose could be 
studied in vps34 knockouts in other yeast strains to 
determine if galactose toxicity is a general 
phenomenon. 
The MVB sorting pathway to the lysosome 
has been implicated in α-synuclein degradation 
(Willingham et al., 2003). Knocking out vps28, a 
component of the ESCRT-I complex of the MVB 
pathway was shown to cause toxicity in cells 
expressing wildtype and mutant forms of α-synuclein 
(Price and Shrestha, 2005). In this study, we have 
shown that α-synuclein causes non-specific toxicity in 
vps34 yeast. Future research will examine several other 
vps proteins, like vps22 and vps27 in mediating α-
synuclein toxicity. 
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Methods 
 
Strains and Transformation: 
 
A30P and E46K mutant α-synuclein were created using 
site directed mutagenesis from human wild type α-
synuclein (Invitrogen). A53T mutant alpha-synuclein 
Figure 7. Growth curve analysis of vps34 grown in glucose 
and galactose. When grown in glucose, both strains reach 
saturation density by 24 hours. In galactose, vps34 do not grow 
until 24 hours post induction, however, the parent strain attains a 
density of about 1.5 at the same time point. 
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and human wild type α-synuclein cDNAs were gifts 
from Christopher Ross (John Hopkins University). In 
order to tag the synuclein cDNAs with GFP, the 
synuclein cDNAs were subcloned into the mammalian 
pcDNA3.1/C-terminal GFP expression vector 
(Invitrogen). After amplification, the synucleins were 
subcloned into pYES2.1/V5-His-TOPO yeast 
expression vector (Invitrogen). α-Synuclein expression 
plasmids were transformed into competent E. coli 
grown on LB ampicillin media for selection. Plasmids 
were then isolated and transformed as described 
(Burke, 2000) into URA-3 deficient S. cerevisiae 4741, 
and vps34 strains. Yeast cells were grown on synthetic-
complete media lacking uracil (SC-Ura) for selection. 
PCR was used to confirm the presence of α-synuclein 
in the pYES2.1 expression plasmids. α-Synuclein 
expression was controlled with the galactose inducible 
promoter(GAL1) in the pYES2.1 vector. The parent 
pYES2.1expression plasmid (Invitrogen) and GFP in 
pYES2.1 vector were used as controls. 
 
Cell Lysates: 
 
BY 4741, and vps34 knockout strains with wild-type α-
synuclein-GFP, A30P-GFP, E46K-GFP, A53T-GFP, 
GFP and parent plasmid were grown overnight at 30˚C 
in a shaking incubator at 200rpm in 10mL SC-URA 
glucose. Cells were washed three times with 10mL H2O 
and resuspended in 2ml H2O. To induce protein 
expression, 1mL of cell suspension was used to 
inoculate 25ml of SC-URA galactose. Cultures were 
then incubated for 24 hours at 30˚C, in a shaking 
incubator at 200rpm. Cells in each culture were counted 
to determine the cell density. 2.5 x 107 cells were taken 
from each culture and washed with 1ml 50mM Tris (pH 
7.5) and 10mM NaN3 [ 100ml: 95mL of H2O; 5mL of 
Tris 1M pH 7.5; 0.06501g NaN3]. Cells were 
resuspended in 30µL Electrophoresis Sample Buffer 
[(ESB) 2% SDS, 80mM Tris (pH6.8), 10% glycerol, 
1.5% DTT, 1 mg/mL bromophenol blue], and various 
protease inhibitors and solubilizing agents [1% Triton-X 
100, ImM phenylmethylsulfonyl fluoride (PMSF), 1mM 
benzamide, 1mM sodium orthovanadate, 0.7µg/mL 
pepstaton A, 0.5µg/mL leupeptin, 10µg/mL E64, 
2µg/mL aprotinin and 2µg/ml chymostatin]. The cell 
mixtures were then vortexed and heated at 100˚C for 3 
min. 0.3 grams of 0.5mm glass beads were added to 
the cell mixtures and vortexed for 2 minutes. 70 µL ESB 
was added to each tube and samples were heated 
again at 100˚C for 1 minute. 
 
Western Analysis: 
 
20µL cell lysates were loaded into 10-20% Tris-Glysine 
SDS gels (Invitrogen) and electrophoresed in 1x Tris-
Glycine SDS running buffer [(diluted to 1x from 10x): 
29.0g Tris Base, 144.0g Glycine, 10.0g SDS, 1.0L Di 
H2O, pH 8.3], at 130 volts.10µL of SEEBLUE protein 
ladder was used. Gels were then transferred onto 
polyvinylidene difluoride (PVDF) membranes, in 1x 
transfer buffer [(diluted to 1x from 25x): 18.2g Tris base, 
90.0g Glycine, to 500mL DiH2O, pH 8.3]. PVDF 
membranes were presoaked in methanol, H2O and 1x 
transfer buffer. The PVDF membrane was placed on a 
foam pad immersed in 1x transfer buffer. The gel was 
placed on the PVDF membrane and another foam pad 
soaked in transfer buffer was placed onto the gel. The 
protein was transferred for 1.5 hours at 30 volts. 
 Western Breeze® Chromogenic 
Immunodetection protocol was used to probe for the 
proteins of interest. Membranes were placed in 10mL of 
blocking solution (Western Breeze) and incubated for 
30 minutes on a rotary shaker set at 1 revolution/sec. 
Membranes were rinsed twice with 20 mL of H2O for 5 
minutes each time. Primary antibody solution was 
prepared by diluting the Anti–V5 AP 1° in 7mL of H2O, 
2mL Blocker/Diluent (Part A) and 1mL Blocker/Diluent 
(Part B). The dilution was 1:2000 (5 µL in 10mL of 
Primary Antibody Diluent). Membranes were incubated 
with 10mL of Primary antibody diluent for 1 hour. 
Antibody was removed and saved, and then 
membranes were washed four times with 20 mL of 
Antibody Wash for 5 minutes each time. For PGK 
controls, the membranes were incubated in 10mL of 
Secondary Antibody Solution for 30 minutes, and 
washed four times with 20 mL of Antibody Wash for 5 
minutes each time. Membranes were then rinsed with 
20mL of water for 2 minutes, thrice. 5mL of 
Chromogenic Substrate was used to incubate the 
membranes until bands of desired intensity could be 
seen. Membranes were washed again with 20 ml of 
water three times after which they were dried on a 
clean piece of filter paper under infrared light.  
 
Coomasie Blue Staining: 
 
After protein samples were run on the 10-20% Tris-
Glysine SDS gel, the gel was stained with Coomassie 
Blue [Coomassie Staining Solution:50% (v/v) 
methanol,0.05% (v/v) Coomassie brilliant blue R-250 
(Bio-Rad or Pierce), 10% (v/v) acetic acid, 40% H2O]. 
The solution was prepared in deionised water, by 
dissolving the Coomassie brilliant blue R-250 in 
methanol before adding acetic acid and water. Staining 
was carried on for two hours. The gel was then 
destained with Destaining Solution [7% (v/v) acetic 
acid, 5% (v/v) methanol, 88% H2O], overnight on a 
rotary shaker. The gel was then washed three times, for 
two minutes each time in deionised water (50mL). 
35mL of Gel-Dry Drying Solution was added to the gel-
tray and shaken for 5minutes in the StainEase gel 
Staining Tray. A sheet of cellophane was immersed in 
the Gel-Dry Drying Solution for 20 seconds, after which 
it was placed on one side of the DryEase Gel Drying 
Frame. Another wetted cellophane was put on top of 
the gel and air bubbles and wrinkles were removed. 
The frame was aligned and the plastic clamps were 
fastened onto the four edges of the frames. The gel 
dryer assembly was allowed to sit upright on a bench 
top for 48 hours. 
 
Toxicity Analysis: 
 
Growth Curve: For the OD600 analysis, transformed 
knockouts and the 4741 parent strain were grown 
overnight in 10ml of SC-URA glucose at 30°C in a 
shaking incubator at 200 rpm. Cells were harvested at 
1500 x g for 5 min at 4°C, and were washed twice with 
5 mL H2O. Cells were resuspended in 10 mL H2O and 
were counted. Flasks with 35mL SC-URA galactose 
and 35ml SC-URA glucose (for controls) were 
inoculated to a 2.0 x 106 cells/mL density. Absorbance 
readings were taken at 0,3,6,12,18,24,36 and 48 hours 
at 600nm using a Hitachi-U-2000 Spectrophotometer. 
Absorbance readings were plotted against time points 
to produce a growth curve.  
 
Spotting: 
                                                                                
Transformed knockouts and 4741 parent strain were 
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grown in 10mL SC-URA glucose overnight at 30°C in a 
shaking incubator at 200rpm. Cells were harvested at 
1500 x g for 5 min at 4°C, and were washed twice with 
5 mL H2O. Cells were resuspended in 10 mL DI H2O 
and counted. 2.0 x 107 cells/mL were removed from the 
cultures and resuspended in 1mL H2O. 100µl of this 
culture was added to the first lane of a microtiter plate. 
The next 5 lanes contained 80µl H20. 20µL of the 
100µL of culture was removed from the first lane and 
added to the second. After mixing, 20 µL from the 
second lane was pipetted and added to the third lane 
and so on, until there were 5 lanes with five-fold serial 
dilutions for each cell culture. These cells were plated 
by inserting a frogger into the microtiter plate and 
plating cells onto SC-URA glucose and SC-URA 
galactose media plates. Plates were grown at 30°C for 
3 days and pictures were taken.  
 
Note: Eukaryon is published by students at Lake Forest 
College, who are solely responsible for its content. The 
views expressed in Eukaryon do not necessarily reflect 
those of the College. Articles published within Eukaryon 
should not be cited in bibliographies. Material contained 
herein should be treated as personal communication 
and should be cited as such only with the consent of 
the author. 
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